A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma

被引：0
|
作者：
Younes, A.
Fanale, M.
Pro, B.
McLaughlin, P.
Neelapu, S.
Fayad, L.
Wedgwood, A.
Dubay, M.
Backstrom, J.
Martell, R. E.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] MethylGene, Montreal, PQ, Canada
[3] Pharmion Corp, Kansas City, KS USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8000
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II study of MGCD0103, a novel oral isotype-selective histone deacetylase inhibitor, in patients with relapsed or refractory Hodgkin lymphoma
    Younes, A.
    Pro, B.
    Fanale, M.
    McLaughlin, P.
    Neelapu, S.
    Fayad, L.
    Wedgwood, A.
    Li, Z.
    Ward, R.
    Martell, R. E.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 28 - 29
  • [2] Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study
    Younes, A.
    Andreadis, C.
    Assouline, S.
    Rizzieri, D.
    Wedwood, A.
    McLaughlin, P.
    Laille, E.
    Li, Z.
    Martell, R. E.
    Crump, M.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 162 - 162
  • [3] Treatment of relapsed or refractory lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study
    Younes, Anas
    Wedgwood, Amanda
    McLaughlin, Peter
    Andreadis, Charalambos
    Assouline, Sarit E.
    Li, Zuomei
    Martell, Robert E.
    Dubay, Marja
    Patterson, Tracy-Ann
    Ward, Michelle R.
    Crump, Michael
    [J]. BLOOD, 2007, 110 (11) : 758A - 758A
  • [4] Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study
    Crump, M.
    Andreadis, C.
    Assouline, S.
    Rizzieri, D.
    Wedgwood, A.
    McLaughlin, P.
    Laille, E.
    Li, Z.
    Martell, R. E.
    Younes, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin lymphoma (HL)
    Younes, A.
    Kuruvilla, J.
    Pro, B.
    Wedgwood, A.
    Li, Z.
    Drouin, M.
    Patterson, T.
    Ward, R.
    Martell, R. E.
    Bociek, R. G.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 128 - 128
  • [6] Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL)
    Bociek, R. G.
    Kuruvilla, J.
    Pro, B.
    Wedgwood, A.
    Li, Z.
    Drouin, M.
    Patterson, T.
    Ward, R.
    Martell, R. E.
    Younes, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Mocetinostat (MGCD0103), An Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, Produces Clinical Responses In Relapsed/Refractory Hodgkin Lymphoma (HL): Update From a Phase II Clinical Study
    Younes, Anas
    Bociek, R. Gregory
    Kuruvilla, John
    Laneuville, Pierre
    Fung, Henry C.
    Drouin, Michel
    Patterson, Tracy
    Besterman, Jeffrey
    Martell, Robert E.
    [J]. BLOOD, 2010, 116 (21) : 735 - 735
  • [8] Phase I study of an oral isotype-selective histone deacetylase (HDAC) inhibitor in patients (pts) with advanced solid tumors
    Siu, L. L.
    Carducci, M.
    Chen, E. X.
    Maclean, M.
    Pili, R.
    King, S.
    Patterson, T.
    Li, Z.
    Kalita, A.
    Reid, G. K.
    [J]. EJC SUPPLEMENTS, 2006, 4 (12): : 94 - 95
  • [9] Resminostat In Relapsed or Refractory Hodgkin Lymphoma: Initial Results of the SAPHIRE Phase II Trial with a Novel Oral Histone Deacetylase (HDAC) Inhibitor
    Walewski, Jan
    Paszkiewicz-Kozik, Ewa
    Borsaru, Gabriela
    Moicean, Andreea
    Warszewska, Agnieszka
    Strobel, Klaus
    Biggi, Alberto
    Hauns, Bernhard
    Mais, Anna
    Henning, Stefan W.
    Hentsch, Bernd
    [J]. BLOOD, 2010, 116 (21) : 1159 - 1159
  • [10] INITIAL RESULTS FROM THE SAPHIRE STUDY: A PHASE II TRIAL WITH THE NOVEL ORAL HISTONE DEACETYLASE (HDAC) INHIBITOR RESMINOSTAT IN RELAPSED OR REFRACTORY HODGKIN'S LYMPHOMA PATIENTS
    Walewski, J.
    Paszkiewicz-Kozik, E.
    Borsaru, G.
    Moicean, A.
    Warszewska, A.
    Strobel, K.
    Biggi, A.
    Hauns, B.
    Mais, A.
    Henning, S.
    Hentsch, B.
    [J]. HAEMATOLOGICA, 2010, 95 : S27 - S27
12345